Home ENGLISH MAGAZINE Multi-resistance: non need to modify antibiotics, now carbo-lipids enhance the killing

Multi-resistance: non need to modify antibiotics, now carbo-lipids enhance the killing

Antibiotics are medicines used to prevent and treat bacterial infections. When the bacteria change in response to these drugs, they become antibiotic-resistant. They become very difficult to treat, and the number of cases is growing by the minute. In 2013, the Centers for Disease Control and Prevention reported that at least 2 million people get an antibiotic-resistant infection each year in the United States. Of these, 23,000 people die. One of the deadliest superbugs today is the Methicillin-resistant Staphylococcus aureus (MRSA), which is a resistant type of bacteria that commonly affects patients in health care settings, wherein they acquire potentially life-threatening infections. In some cases, the patients get the infection in the community. In the United States alone, about 80,461 people get infected with MRSA each year, and it kills about 11,285 people every year. Antibiotic resistance is a big threat to global health, and a growing number of infections are now becoming harder to treat. Now, a team of researchers may have found a potent weapon against antibiotic-resistant bacteria, which can help treat persistent infections.

The researchers at the University of North Carolina Health Care developed a new way to make antibiotics more potent and able to kill disease-causing pathogens. Published in the journal Cell Chemical Biology, the study showed how the scientists formulated a way to make bacteria more vulnerable to some common antibiotics. In the study, the researchers discovered that incorporating molecules dubbed as rhamnolipids can make certain antibiotics a hundred times more powerful against Staphylococcus aureus, which causes many infections that become persistent despite treatment. The rhamnolipids successfully loosen up the outer membranes of the bacteria, making aminoglycoside molecules to enter easily and faster. The typical treatments for many Staphylococcus strains can’t kill the bacteria because of two factors – antibiotic resistance or less vulnerability. For instance, the bacterium can adapt its metabolism to make it possible to survive in low-oxygen areas, such as the mucus-filled lungs of people suffering from cystic fibrosis.

When this happens, the bacteria adapt to its environment, making the outer wall or membrane impermeable to aminoglycoside antibiotics, including tobramycin. But, in the study, the researchers found that rhamnolipids can enhance the potency of tobramycin against the bacteria.The new method could help many people against superbugs, which can cause serious complications if they’re left untreated. Also, it could help save many lives. Dr. Brian Conlon, assistant professor in the Department of Microbiology and Immunology at the UNC School of Medicine and study co-author, said: “There’s a great need for new ways to kill bacteria that tolerate or resist standard antibiotics, and to that end we found that altering membrane permeability to induce aminoglycoside uptake is an extremely effective strategy against S. aureus“. In a series of experiments, they tested rhamnolipid-tobramycin combinations against Staphylococcus aureus that are difficult to eradicate via traditional methods.

They discovered that rhamnolipids enhance tobramycin’s efficacy against Staphylococcus aureus, MRSA, tobramycin-resistant S. aureus strains from patients with cystic fibrosis, and some strains of S. aureus that have reduced susceptibility to antibiotics. Tobramycin doses that normally would have little or no effect on these S. aureus populations quickly killed them when combined with rhamnolipids. Subsequently, they found that rhamnolipids can alter the membrane of the bacteria, making it permeable for the antibiotic to penetrate. The team tested several antibiotics, including the regular aminoglycosides tobramycin, amikacin, gentamicin and kanamycin, which all had enhanced potency. This is advantageous, since bacteria are usually resistant to these class of antibiotics by firstly uptaking them, then modifying them with their own enzymatic metabolism. The efficacy and potency of the antibiotics were not only effective against S. aureus but also other species, such as Clostridium difficile, which could be among fatal causes of diarrheal disease in hospitals.

Dr. Conlon concluded: “There’s a huge number of bacterial interspecies interactions that could be influencing how well our antibiotics work. We aim to find them with the ultimate goal of improving the efficacy of current therapeutics and slowing the rise of antibiotic resistance.

  • Edited by Dr. Gianfrancesco Cormaci, PhD, specialist in Clinical Biochemistry.

Scientific references

Radlinski LC et al., Conlon BP. Cell Chem Biol. 2019 Aug 6.

Ramos da Silva A et al. Colloids Surf B Biointerf. 2019 Sep; 181:234-43.

Shen Y, Li P, Chen X et al. Microb Drug Resist. 2019 Jun 18.

Dott. Gianfrancesco Cormaci
- Laurea in Medicina e Chirurgia nel 1998 (MD Degree in 1998) - Specialista in Biochimica Clinica nel 2002 (Clinical Biochemistry residency in 2002) - Dottorato in Neurobiologia nel 2006 (Neurobiology PhD in 2006) - Ha soggiornato negli Stati Uniti, Baltimora (MD) come ricercatore alle dipendenze del National Institute on Drug Abuse (NIDA/NIH) e poi alla Johns Hopkins University, dal 2004 al 2008. - Dal 2009 si occupa di Medicina personalizzata. - Guardia medica presso strutture private dal 2010 - Detentore di un brevetto sulla preparazione di prodotti gluten-free a partire da regolare farina di frumento immunologicamente neutralizzata (owner of a patent concerning the production of bakery gluten-free products, starting from regular wheat flour). - Responsabile del reparto Ricerca e Sviluppo per la società CoFood s.r.l. (leader of the R&D for the partnership CoFood s.r.l.) - Autore di un libro riguardante la salute e l'alimentazione, con approfondimenti su come questa condizioni tutti i sistemi corporei. - Autore di articoli su informazione medica, salute e benessere sui siti web salutesicilia.com e medicomunicare.it